ASCO: Avastin ups survival in platinum-resistant ovarian cancer

This article originally appeared here.
Share this content:
ASCO: Avastin Ups Survival in Platinum-Resistant Ovarian CA
ASCO: Avastin Ups Survival in Platinum-Resistant Ovarian CA

(HealthDay News) -- For women with platinum-resistant ovarian cancer, the addition of bevacizumab (Avastin) to chemotherapy is associated with improved progression-free survival, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Eric Pujade-Lauraine, M.D., Ph.D., from the Université de Paris Descartes, and colleagues conducted a phase III randomized trial of bevacizumab involving 361 patients with platinum-resistant ovarian cancer. Patients whose disease had progressed not more than six months after four or more cycles of platinum-based therapy were eligible for inclusion. Exclusion criteria included refractory ovarian cancer, history of bowel obstruction, and two or more previous anticancer regimens. Patients were randomly allocated to receive chemotherapy (pegylated liposomal doxorubicin, topotecan, or weekly paclitaxel) alone (182 patients) or chemotherapy with bevacizumab (179 patients). The primary end point was progression-free survival.

After a median follow-up of 13.5 months, the researchers found that 75 percent of the bevacizumab group had recurrence, compared with 91 percent of the chemotherapy-alone group. In the bevacizumab group, the median progression-free survival was 6.7 months, compared with 3.4 months in the chemotherapy-alone group.

"These results are very significant because the addition of bevacizumab offers a new treatment option for the 20 percent of women who have primary platinum-resistant disease, as well as those whose disease later becomes platinum-resistant," Pujade-Lauraine said in a statement. "For the first time in platinum-resistant ovarian cancer, we have been able to significantly improve progression-free survival with a combination therapy."

Several authors disclosed financial ties to pharmaceutical companies, including Roche Diagnostics, which manufactures Avastin.

More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs